Nuglim M 1 Forte Tablet PR is a combination oral antihyperglycemic agent containing Glimepiride 1mg and Metformin 1000mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, enhances pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, facilitating better glucose uptake by tissues. This dual mechanism effectively controls hyperglycemia in patients inadequately managed by diet and exercise alone. Nuglim M 1 Forte Tablet PR is typically prescribed when monotherapy with either agent is insufficient to achieve glycemic targets. The sustained-release formulation ensures gradual drug release, promoting stable plasma concentrations and minimizing gastrointestinal side effects commonly associated with metformin. It is essential to monitor renal function prior to and during therapy due to the risk of lactic acidosis, a rare but serious adverse effect linked to metformin. Patients should be advised on lifestyle modifications including diet and exercise to optimize therapeutic outcomes. Contraindications include severe renal impairment, metabolic acidosis, and hypersensitivity to components. Regular blood glucose monitoring is recommended to adjust dosage and prevent hypoglycemia, particularly due to glimepiride’s insulinotropic action. Nuglim M 1 Forte Tablet PR provides an effective and convenient option for comprehensive glycemic control in type 2 diabetes management.

Dosage & How to Use